AZTR: Azitra, Inc. Earnings growth forecast for next year

Azitra Corporation (AZTR) - corporate logo

The forward EPS dynamics model for Azitra, Inc. (AZTR) demonstrates stability against a backdrop of a neutral geopolitical climate in the US. The business relies on unique patents for the treatment of ichthyosis, overcoming stringent FDA controls. Monetization of the bacterial platform guarantees long-term sustainability in dermatology, while the latest parameter stands at 68.70, confirming the maturity of the fundamental profile of Azitra, Inc.

AZTR - Azitra Inc Net earnings per share change forecast for next year over the range 02/21/2024 - 11/12/2026

Financial and market metric breakdowns for azitrainc.com (AZTR)

- price and consensus price forecast:
Price Chart Azitra Corp|AZTR - Broker Consensus Forecast
- market capitalization information:
Market Capitalization Azitra|AZTR - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Azitra|AZTR - Net Asset Value|Market Capitalization to Book Value Ratio azitrainc.com|AZTR - Company Total Asset Base
- debt and liquidity details:
Total Debt to Equity Ratio Azitra, Inc.|AZTR - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Azitra|AZTR - Aggregate Debt Obligations|Debts to Book Capitalization Azitra|AZTR - Company Long-Term Debts|Company Current Liabilities Azitra|Quick Ratio azitrainc.com
- earnings and market ratios statistics:
AZTR - Net Financial Result|Expected Profit Azitra, Inc.|AZTR - Price to Earnings Multiple|Forward P/E Multiple Azitra, Inc.|AZTR - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Azitra|AZTR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Azitra|AZTR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months azitrainc.com|AZTR - Earnings per share trend in current year|Expected earnings per share growth for next year Azitra, Inc.
Fundamental company valuation:Azitra Corp, AZTR
Brand item of Azitra

This indicator visualizes the analysts' consensus forecast for earnings per share (EPS) changes, reflecting the real-time adjustment of financial models. By analyzing the projected EPS trend for the coming year, investors can assess market expectations, which for Azitra, Inc. (AZTR) remain speculative due to a lack of revenue and the biotech's total dependence on external investment for clinical trials.

Main competitors

Net earnings per share growth forecast for next year Krystal Corp|Projected earnings per share growth rate for next year APGE (Apogee Corp)|Earnings growth forecast for next year ARQT|Earnings growth forecast for next year vcel.com (VCEL)|Oruka Therapeutics - Expected earnings per share growth for next year|SMTI (Sanara MedTech, Inc.) - Net earnings per share change forecast for next year|DBV Technologies SA - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Solesence Inc SLSN|DERM (journeymedicalcorp.com) - Expected earnings per share growth for next year|FBRX: Projected earnings per share increase next year|Net earnings per share growth forecast for next year Empro Group|SLGL: Expected earnings per share trend next year|Earnings growth forecast for next year AXIL|Earnings growth forecast for next year Medicus Pharma Corp (MDCX)|Verrica Pharmaceuticals Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year HOTH|Biofrontera Inc - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year VYNE Therapeutics VYNE|sonomapharma.com (SNOA) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year QNRX|DRMA (Dermata Therapeutics) - Earnings growth forecast for next year|Expected earnings per share growth for next year elevaiskincare.com (ELAB)|Expected earnings per share growth for next year RVNC (Revance Therapeutics, Inc.)